Literature DB >> 8386667

Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination.

W M Kast1, R M Brandt, C J Melief.   

Abstract

Sendai virus nuclear protein peptides of different lengths were titrated in peptide vaccination experiments. We observed that peptide length was not important in inducing cytotoxic T lymphocyte-mediated protective immunity in vivo against a challenge with a lethal dose of virus. These results suggest that long peptides are trimmed in vivo to peptides that fit into the groove of major histocompatibility complex class I molecules. In addition several adjuvants were screened for their effectiveness in peptide vaccination protocols. Incomplete Freund's adjuvant and Titermax turned out to be useful, whereas alum was much less effective.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386667     DOI: 10.1002/eji.1830230534

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help.

Authors:  C Fayolle; U M Abdel-Motal; L Berg; E Deriaud; M Jondal; C Leclerc
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

Review 2.  Peptides for Vaccine Development.

Authors:  Ian W Hamley
Journal:  ACS Appl Bio Mater       Date:  2022-02-23

3.  Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

Authors:  R Schirmbeck; K Melber; T Mertens; J Reimann
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

4.  A self-reactive class I-restricted T-cell response of H-2b mice to determinants of the V beta 8.2 domain of the T-cell receptor for antigen.

Authors:  A Kuhröber; R Schirmbeck; J Reimann
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

5.  gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.

Authors:  L S Kierstead; E Ranieri; W Olson; V Brusic; J Sidney; A Sette; Y L Kasamon; C L Slingluff; J M Kirkwood; W J Storkus
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

6.  Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.

Authors:  Benjamin Uttenthal; Irma Martinez-Davila; Adam Ivey; Charles Craddock; Frederick Chen; Andras Virchis; Panagiotis Kottaridis; David Grimwade; Asim Khwaja; Hans Stauss; Emma C Morris
Journal:  Br J Haematol       Date:  2013-11-16       Impact factor: 6.998

Review 7.  Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.

Authors:  Brett J Hos; Elena Tondini; Sander I van Kasteren; Ferry Ossendorp
Journal:  Front Immunol       Date:  2018-04-26       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.